456
Participants
Start Date
March 28, 2022
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2027
Ribociclib + Letrozole OR Fulvestrant
Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
Palbociclib + Letrozole OR Fulvestrant
Endocrine Therapy will be selected by the investigator. For premenopausal women and men: LHRH agonist once every 4 weeks
Paclitaxel +/- Tislelizumab
Patients in this arm could receive as the first line of therapy
IOB-Institute of Oncology. Hospital Quironsalud Barcelona, Barcelona
Complejo Hospitalario San Pedro de Alcántara, Cáceres
Montefiore, The Bronx
Hospital Clínico Universitario de A Coruña, A Coruña
Hospital Clínico Universitario de Santiago CHUS, Santiago de Compostela
Institut Català d' Oncologia de Girona (ICO Girona), Girona
Hospital Universitario Virgen de las Nieves, Granada
H. Clínico San Cecilio de Granada, Granada
Sinai of Baltimore, Baltimore
Complejo Asistencial Universitario de León, León
Hospital Universitari Arnau de Vilanova de Lleida, Lleida
Edwards Comprehensive Cancer Center, Huntington
Novant Health Care, Winston-Salem
University of North Carolina Lineberger, Chapel Hill
Hospital Universitario La Princesa, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital La Paz, Madrid
Centro Integral Oncológico Clara Campal (CIOCC), Madrid
Hospital Universitario Puerta de Hierro de Majadahonda, Madrid
Hospital Universitario de Fuenlabrada, Fuenlabrada
Hospital Virgen de la Victoria, Málaga
Upstate Carolina Medical Center, Spartanburg
The Medical University of South Carolina, Charleston
Hospital Universitario Morales Meseguer, Murcia
Hospital Universitario Virgen de la Arrixaca, El Palmar
Memorial Regional Hospital, Hollywood
University of Miami, Coral Gables
Mount Sinai Florida, Miami
Morton Plant Hospital, Clearwater
Hospital Universitario de Gran Canaria Doctor Negrin, Las Palmas
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Baptist Memorial Health Care, Oxford
Hospital Universitario Marqués de Valdecilla, Santander
University of Kentucky, Markey Cancer Center, Lexington
Hospital Virgen de la Macarena, Seville
Hospital Quiron Salud Sagrado Corazon Sevilla, Seville
Hospital Universitario Virgen del Rocio, Seville
Hospital Sant Joan de Reus, Reus
Ohio State University Comprehensive Cancer Center, Columbus
Dayton Clinical Oncology, Kettering
Instituto Valenciano de Oncología (IVO), Valencia
Hospital Clinico Universitario de Valencia, Valencia
Hospital de Basurto, Bilbao
Hospital Clínico Universitario Lozano Blesa, Zaragoza
Unv. Wisconsin, Madison
Northwestern, Chicago
Carle Cancer Center, Urbana
University of Nebraska Medical Center, Omaha
Nevada Cancer Research Foundation, Las Vegas
Legacy Good Samaritan Hospital and Medical Cente, Portland
Providence Portland Medical Center, Portland
Bon Secours Memorial Regional Medical Center, Mechanicsville
Dana Faber Cancer Institute, Boston
NHOH, Londonderry
Nothwell Health, New York
Hospital Senhora da Oliveira - Guimarães, Creixomil
IPO Lisboa, Lisbon
Hospital Beatriz Ângelo, Loures
Instituto Portugues de Oncologia de Porto Francisco Gentil, EPE, Porto
Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia
Hospital Son Llàtzer, Palma de Mallorca
Institut Català d' Oncologia (ICO Badalona), Badalona
Hospital del Mar, Barcelona
Institut Català d'Oncologia (ICO Hospitalet), L'Hospitalet de Llobregat
Hospital General de Catalunya, Sant Cugat del Vallès
Hospital General Universitario de Alicante, Alicante
Vall d´Hebron University Hospital, Barcelona
Hospital Clinic de Barcelona, Barcelona
Collaborators (1)
Novartis
INDUSTRY
Alliance Foundation Trials, LLC.
OTHER
SOLTI Breast Cancer Research Group
OTHER